Data show that in adult patients with type 2 diabetes with increased cardiovascular (CV) risk, compared with titrated insulin glargine, all three doses of tirzepatide show superiority in reducing blood sugar and body weight: treatment for 52 weeks, with curative effect Estimation (efficacy estimand) statistical analysis method, the highest dose of tirzepatide (15 mg, once a week) reduces blood glucose level (A1C) from baseline by 2.58%, and weight from baseline by 11.7 kg (25.8 pounds, 13.0%), and titration Insulin glargine reduced A1C from baseline by 1.44% and body weight increased by 1.9 kg (4.2 lbs, 2.2%) from baseline
Dutta SK, Verma S, Jain V, Surapaneni BK, Vinayek R, Phillips L, Nair PP
and ensure the final product abides by Current Good Manufacturing Processes (CGMP), which guarantees the medication is sterile if applicable (as in the case of injectables like GLP-1s) and will remain stable for usually a couple years
Do that, and the rest will follow.
Secondarily I'd add a takeaway for me was he seems fairly confident that inflation will be coming down, and I think he still believes the labor market is cooling
